Martin Vazquez - Feb 1, 2023 Form 4 Insider Report for Outset Medical, Inc. (OM)

Role
Chief Operating Officer
Signature
By: John L Brottem For: Martin Vazquez
Stock symbol
OM
Transactions as of
Feb 1, 2023
Transactions value $
-$629,494
Form type
4
Date filed
3/2/2023, 05:15 PM
Previous filing
Jan 30, 2023
Next filing
Feb 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OM Common Stock Options Exercise $19.4K +5K +4.79% $3.88* 109K Feb 1, 2023 Direct
transaction OM Common Stock Sale -$140K -5K -4.57% $27.91 104K Feb 1, 2023 Direct F1, F2
transaction OM Common Stock Options Exercise $25.2K +6.5K +6.22% $3.88* 111K Feb 2, 2023 Direct
transaction OM Common Stock Sale -$195K -6.5K -5.86% $30.00 104K Feb 2, 2023 Direct F1
transaction OM Common Stock Options Exercise $25.2K +6.5K +6.22% $3.88* 111K Feb 2, 2023 Direct
transaction OM Common Stock Sale -$195K -6.5K -5.86% $30.00 104K Feb 2, 2023 Direct F1
transaction OM Common Stock Options Exercise $25.2K +6.5K +6.22% $3.88* 111K Feb 2, 2023 Direct
transaction OM Common Stock Sale -$195K -6.5K -5.86% $30.00 104K Feb 2, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OM Performance Options (right to buy) Options Exercise $0 -5K -6.85% $0.00 68K Feb 1, 2023 Common Stock 5K $3.88 Direct F3
transaction OM Performance Options (right to buy) Options Exercise $0 -6.5K -9.56% $0.00 61.5K Feb 2, 2023 Common Stock 6.5K $3.88 Direct F3
transaction OM Performance Options (right to buy) Options Exercise $0 -6.5K -10.57% $0.00 55K Feb 2, 2023 Common Stock 6.5K $3.88 Direct F3
transaction OM Performance Options (right to buy) Options Exercise $0 -6.5K -11.82% $0.00 48.5K Feb 2, 2023 Common Stock 6.5K $3.88 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from: $27.00 - $27.99 - 3,640 shares; $28.00 - $28.99 - 1,360 shares. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold within the range set forth in this footnote.
F3 In March 2021, following the expiration of the lock-up period in connection with our initial public offering, the applicable performance and market-based vesting conditions were met and the shares underlying this stock option award became fully vested.
F4 In March 2021, following the expiration of the lock-up period in connection with our initial public offering, the applicable performance and market-based vesting conditions were met and the shares underlying this stock option award became fully vested.